CII
INSM icon

CR Intrinsic Investors’s Insmed INSM Stock Holding History

CR Intrinsic Investors’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-193,000
Closed -$3.01M – 312
2013
Q3 		$3.01M Buy
+193,000
New +$2.45M 0.09% 252

Other funds holding INSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

CR Intrinsic Investors's INSM Position: Q4 2013 in Review

CR Intrinsic Investors sold out of Insmed (INSM) in Q4 2013, closing a stake of 193,000 shares — an estimated $3.01M sold.

CR Intrinsic Investors first reported a position in INSM in Q3 2013 and held it in 1 quarter. The position peaked at $3.01M in Q3 2013. 89 funds tracked by Wall St. Rank hold INSM as of Q4 2013.

  • CR Intrinsic Investors reported no remaining Insmed position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 193,000 Insmed shares in Q4 2013, an estimated $3.01M.
  • CR Intrinsic Investors first reported a position in Insmed in Q3 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's Insmed position peaked at $3.01M in Q3 2013.
  • 89 funds tracked by Wall St. Rank held Insmed as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.